Relationship of p 53 , bcl-2 , and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin ’ s Lymphomas

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• CLINICAL SIGNIFICANCE OF BCL2- MBR GENE REARRANGEMENT AND PROTEIN EXPRESSION IN DLBCL: AN ANALYSIS OF 83 CASES

  1994cited by this paper
• Non-Hodgkin's Lymphomas

  1994cited by this paper
• Cell cycle control and cancer chemotherapy

  1994cited by this paper
• Apoptosis and cancer.

  1994cited by this paper
• p53 mutation is associated with progression in follicular lymphomas.

  1993cited by this paper
• The prognostic value of Ki67 immunostaining in non‐Hodgkin's lymphoma

  1988cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• The Value of Immunohistochemistry of P53 and Ki67 in Non-Hodgkin’s Lymphoma

  2019cites this paper
• The Value of Immunohistochemistry of P 53 and Ki 67 in Non-Hodgkin ’ s Lymphoma Dr .

  2019cites this paper
• Mutant p53 in cancer therapy—the barrier or the path

  2018cites this paper
• Diffuse Large B-cell Lymphoma, Differential Diagnosis and Molecular Stratification

  2011cites this paper
• A cytomorphological and immunohistochemical profile of aggressive B-cell lymphoma: high clinical impact of a cumulative immunohistochemical outcome predictor score

  2009cites this paper
• Comparative Mitochondrial Proteomic Analysis of Raji Cells Exposed to Adriamycin

  2009cites this paper
• Usefulness of Immunohistochemistry in Identifi cation of Prognostically Important Subgroups ( GCB and ABC ) in a Heterogeneous Group of Diffuse Large B-cell Lymphomas – a

  2008cites this paper
• Cure Translational Research : Walking the Bridge between Idea and Updated Version

  2006cites this paper
• Prognostic value of GST-π expression in diffuse large B-cell lymphomas

  2003cites this paper
• p53 abnormalities in splenic lymphoma with villous lymphocytes.

  2001cites this paper
• Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma

  2000cites this paper
• Genetic analysis of chemoresistance in primary murine lymphomas

  2000cites this paper
• Clinical implications of p53 mutations

  1999cites this paper
• bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study.

  1998cites this paper
• BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.

  1998cites this paper
• Mouse Lymphoma Model-myc μ E DNA Damage Responses and Chemosensitivity in the References

  year unknowncites this paper